Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep714 | Pituitary: clinical | ECE2015

A case of lung cancer with pituitary metastases presented by diabetes insipidus

Dokmetas H Sebila , Hincal Hande Ogul , Bilici Ahmet

Cancer metastases on pituitary gland are seen rarely. A 71-year-old male was admitted to Endocrinology Department with polydipsia, polyuria, and diplopia. Urine volume was ~5 l/day. In medical history; he had been diagnosed as having non-small cell lung carcinoma with multiple liver and bone metastases 1 year ago. He took chemotherapies with four cycles of paclitaxel, carboplatin, and zoledronic acid for bone metastases and radiation therapy (RT) was given to L4-S1 vertebras. ...

ea0037ep879 | Thyroid cancer | ECE2015

Histhopathological verification of atypia of undetermined significance in Bethesda system

Ozmen Sevilay , Calik Ilknur , Bilici Ahmet Erkan , Timur Ozge , Carlioglu Ayse , Durmaz Senay Arikan , Erdogan Fazli , Kurt Ali

The pathologist cannot easily decide some thyroid fine-needle aspiration biopsy (FNA) into the benign, suspicious, or malignity and this condition are reported as ‘atypia of undetermined significance’ (AUS) or ‘follicular lesion of undetermined significance’ in the Bethesda system. Diagnosis of AUS of a thyroid nodule is leaved an endocrinologist as well as the patients in a difficult situation. However, the risk of malignancy at AUS is ~5–15%. Our aim...

ea0081ep948 | Thyroid | ECE2022

Immune checkpoint inhibitors induced myxedema coma

Sebile Dokmetaş Hatice , Dokmetaş Meric , Bayramgil Ayberk , Karaipek Ku bra , Dorukhan Cavuşoğlu Guneş , Temiz Cansu , İdrisoğlu Cem , Kılıclı Fatih , Bilici Ahmet

Introduction: Myxedema coma is very rare and its mortality is quite high. It is even rarer to occur due to an immune checkpoint inhibitor.Case: A 69-year-old patient presented with complaints of dyspnea, fatigue, edema, and hypotension. He had diabetes mellitus, hypertension, and metastatic lung cancer diagnosis. Three weeks ago, he had taken the 10th cycle of atezolizumab for lung cancer, which he had been taking for 7 months. The patient’s body te...